Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Axsome Therapeutics, Inc.
Eligible subjects were randomized in a 1:1 ratio for up to 5 weeks to be treated with AXS-05 or placebo.
Age
65–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of probable Alzheimer's disease (AD) based on the 2011 National Institute on Aging-Alzheimer Association (NIA-AA) criteria.
Diagnosis of clinically significant agitation resulting from probable AD according to the International Psychogeriatric Association (IPA) provisional definition of agitation.
You may not be if
Patient has dementia predominantly of non-Alzheimer's type.
Unable to comply with study procedures.
Medically inappropriate for study participation in the opinion of the investigator.
Clareo Health | A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
